

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in





Anti-DPGA anthrax [4C] Standard Size Ab03882-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent[™], Kappa

Clone Number: 4C

Alternative Name(s) of Target: DPGA; capsular antigen; γDPGA; gamma DPGA; poly-gamma-d-glutamic

acid; poly-γ-d-glutamic acid; antiphagocytic polypeptide capsule

UniProt Accession Number of Target Protein:
Published Application(s): in vivo, neutralize, ELISA
Published Species Reactivity: Bacillus anthracis

Immunogen: The original antibody was generated by immunizing a chimpanzee with fragmented peptides of poly-γ-D-glutamic acid (γDPGA) capsule of B. anthracis conjugated with either B. anthracis recombinant protective antigen (rPA) or tetanus toxoid (TT).

Specificity: This antibody specifically binds the poly- γ -D-glutamic acid (γ DPGA) capsule of Bacillus anthracis. Bacillus anthracis is surrounded by an antiphagocytic polypeptide capsule composed of poly γ -d-glutamic acid (γ DPGA). The γ DPGA capsule shields the vegetative form of B. anthracis from agglutination by monoclonal antibodies to its cell wall polysaccharide. γ DPGA has been identified recently as a potential target for vaccine development. Bacillus anthracis is a spore-forming bacterium and a causative agent for Anthrax, which is a highly lethal infectious disease in human and poses a great threat as an emerging bioterror agent.

Application Notes: The binding characterization of this antibody to $\gamma DPGA$ of Bacillus anthracis was done using ELISA. The binding affinity of the antibody was measured using surface plasmon resonance. It was reported that the IgG1 version of this antibody binds 10-mer peptide of $\gamma DPGA$ with a binding affinity of Kd= 0.2 nM. It was reported that a single 30- μ g dose of this antibody when given to BALB/c mice 18 h before challenge conferred about 50% protection against a lethal intratracheal spore challenge by the virulent B. anthracis Ames strain. When given 8 h or 20 h after challenge, this antibody provided significant protection against lethal infection (PMID: 21187383). This antibody can be used in treatment of infections with antibiotic-resistant strains (PMID: 22069754).

Antibody First Published in: Chen et al. Pre- and postexposure protection against virulent anthrax

infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2): 739–744. PMID:21187383

Note on publication: Describes the generation of two antibodies against B. anthracis γ DPGA and evaluates their capacity to protect mice against lethal intratracheal spore challenge.

Product Form

Size: 100 μg Purified antibody.

Purification: Protein A affinity purified **Supplied In:** PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.